Dupixent (dupilumab) gets DCGI approval to treat moderate-to-severe atopic dermatitis EP News Bureau Jul 11, 2023 Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement
US FDA accepts Dupixent for priority review in adults with prurigo nodularis EP News Bureau Jun 1, 2022 If approved, Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the US
Pfizer’s phase-III Jade trial shows positive results EP News Bureau Sep 1, 2021 The trial compares the efficacy of abrocitinib and dupilumab for moderate-to-severe atopic dermatitisa